During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee member, Ruben A. Mesa, UT Health San Antonio, San Antonio, US, about whether it is a good idea to use JAK inhibitors (JAKi) in early, or asymptomatic, myelofibrosis (MF).
Should we treat asymptomatic (‘early’) myelofibrosis with JAKi?
JAKi were originally used in more advanced cases of MF and showed positive results in these patients. Now the use of JAKi, specifically ruxolitinib, is being applied to low risk patients.
Subscribe to get the best content related to MPN delivered to your inbox every month
